TrialRheumatology (Oxford, England)2025

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.

Atul Deodhar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.